Edition:
United States

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

0.19USD
16 Feb 2018
Change (% chg)

$-0.01 (-3.21%)
Prev Close
$0.20
Open
$0.20
Day's High
$0.20
Day's Low
$0.19
Volume
29,948
Avg. Vol
34,051
52-wk High
$3.59
52-wk Low
$0.16

Chart for

About

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen... (more)

Overall

Beta: --
Market Cap(Mil.): $7.13
Shares Outstanding(Mil.): 29.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Essa Pharma Qtrly Loss Per Share $0.07

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

Feb 13 2018

BRIEF-Essa Pharma Files For Offering Of About 113.9 Million Common Shares That May Be Offered For Resale By Selling Shareholders

* ESSA PHARMA INC FILES FOR OFFERING OF ABOUT 113.9 MILLION COMMON SHARES THAT MAY BE OFFERED FOR RESALE BY SELLING SHAREHOLDERS - SEC FILING Source text: (http://bit.ly/2Dsiula) Further company coverage:

Jan 22 2018

BRIEF-Bvf Partners Reports 9.9 Percent Passive Stake In Essa Pharma‍​

* BVF PARTNERS L.P REPORTS 9.9 PERCENT PASSIVE STAKE IN ESSA PHARMA INC AS OF JANUARY 5, 2018 - SEC FILING ‍​ Source text - http://bit.ly/2DgNTLE Further company coverage:

Jan 16 2018

BRIEF-Essa Says Intends To Issue Up To 125 Mln Common Shares At $0.20 Per Share

* ESSA ANNOUNCES FILING OF AMENDED AND RESTATED PROSPECTUS SUPPLEMENT AND AN UPDATE TO PREVIOUSLY ANNOUNCED EQUITY OFFERING

Jan 02 2018

BRIEF-Essa Pharma Announces Pricing Of Previously Announced Equity Offering

* ESSA PHARMA ANNOUNCES PRICING OF PREVIOUSLY ANNOUNCED EQUITY OFFERING

Dec 13 2017

BRIEF-ESSA Pharma announces overnight marketed equity offering

* ESSA PHARMA - TO USE NET PROCEEDS OF OFFERING PRIMARILY TO CONTINUE ONGOING PRECLINICAL DEVELOPMENT OF CO'S ANITEN COMPOUNDS Source text for Eikon: Further company coverage:

Dec 12 2017

BRIEF-Essa Pharma Reports Qtrly Loss Per Share Of $0.07

* ESSA PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2017

Dec 11 2017

Earnings vs. Estimates